Sarepta Therapeutics (SRPT) Misses Q1 EPS by 24c, Revenue Beats

Sarepta Therapeutics (NASDAQ: SRPT) reported Q1 EPS of ($0.60), $0.24 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.3 million versus the consensus estimate of $13.86 million.

Company anticipates net revenues for the year will exceed $95 million

(Street sees FY rev of $95.8M)

For earnings history and earnings-related data on Sarepta Therapeutics (SRPT) click here.

You May Also Be Interested In

• Piper Sandler sees Google TPU sales hitting $104BN by 2028
• What past S&P 500 drawdowns reveal about today’s market, according to RBC
• BGC Group reaffirms Q3 2026 revenue and earnings outlook